WA-VOUCHED
Power to the Beeple, and to every other artist, collector, and investor working to expand the boundaries of fine art by bringing works tied to nonfungible tokens (NFTs) to the mainstream.
Vouched and Verisart today announced an industry-first partnership to apply Vouched’s unique digital identity verification technology to Verisart’s first-of-its-kind blockchain certification platform for digital artists and collectors. The partnership is a significant step forward for the NFT art industry, which has recently seen spikes in interest after a piece created by artist Beeple sold for $69.3 million, a new record for purely digital work.
“The rise of NFTs demonstrates that virtually everything in our known history can be adapted to a digital future, from healthcare to banking to real estate, and now fine art,” said John Baird, Co-Founder, and CEO of Vouched. “Identity verification is absolutely foundational to every element of this ongoing digital revolution. We are excited to work with Verisart to bring Vouched’s unmatched AI technology to the world of NFT art, helping to unleash creativity for artists and enable more confident investing for collectors.”
Vouched’s identity verification platform will be used as part of Verisart’s new patent-pending global standard for digital art certification, enabling creators, collectors, and dealers to easily create digital certificates registered on the blockchain.
“While there may be a lot of hype around the NFT art market right now, it highlights an important advancement that is here to stay and will continue to reshape how we create, authenticate and value those creations moving forward,” said Robert Norton, CEO of Verisart. “Verisart is pioneering the capability to apply blockchain to certification in the art and collectibles market. We support creativity by facilitating trusted transactions and empowering artists to establish their careers and legacies, regardless of what their works sell for.”
Starting immediately, artists can create secure certificates of authenticity for their NFTs on Verisart using Vouched’s platform by using their ID and Vouched’s facial recognition tools to ensure they are who they say they are. The same process is being utilized for collectors on Verisart to verify purchaser identity, creating an extra layer of security for both the artist and the buyer.
About Vouched
Vouched is proprietary artificial intelligence and computer vision that powers end-to-end visual identity verification and fraud detection online in real-time. An expert on more than 450 government-issued identity documents, including driver’s licenses, passports, and permanent resident cards, in 50+ countries, Vouched helps banks, gig and sharing companies, and hospital and healthcare providers verify and onboard users to provide access to life’s most critical services instantly.
For more information on Vouched, visit www.vouched.id , or contact Vouched communications at 1-800-674-8798 or press@vouched.id .
About Verisart
Verisart is an award-winning certification service enabling artists, galleries, and collectors to create certificates of authenticity securely registered on the blockchain. Founded in 2015 as the first company to apply blockchain to certification in the art and collectibles market, Verisart has pioneered a new patent-pending global standard for certification. Over 20,000 artworks have been certified on the platform by more than 5000 artists including Shepard Fairey, Ai Weiwei, Jules De Balincourt, Penny Slinger, and Derek Boshier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005446/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom